Subsequent murine studies showed additive treatment effects of a TLR9 agonist in combination with anti-PD-1 or anti-PD-L1 therapy in hepatoma cell lines and HCC (see Table 2) (76, 190). Here, CD274 is linked to hepatocellular carcinoma.